Holen Sie sich die Stockscreener-App
97.50
0.84%
0.81
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$96.69
Offen:
$97.25
24-Stunden-Volumen:
8.65M
Relative Volume:
0.91
Marktkapitalisierung:
$168.71B
Einnahmen:
$46.59B
Nettoeinkommen (Verlust:
$5.41B
KGV:
31.51
EPS:
3.0938
Netto-Cashflow:
$7.38B
1W Leistung:
-3.74%
1M Leistung:
-11.74%
6M Leistung:
-5.22%
1J Leistung:
-26.69%
1-Tages-Spanne:
$95.06
$97.59
1-Wochen-Bereich:
$95.06
$101.76
52-Wochen-Spanne:
$81.97
$135.37
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
97.50 | 168.71B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Abbott settled a government infant formula lawsuit for nearly $385 million. - Claim Depot
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
In 1935, An Illinois Secretary Bought 3 Shares Of Her Company's Stock For $180. She Never Sold A Single Share And Always Reinvested Dividends. By The Time She Died In 2010 Her 3 Abbott Shares Had Turned Into $7.2 Million. - 247wallst.com
Abbott Laboratories’ Quarterly Earnings Preview: What You Need to Know - Barchart.com
Abbott rolls out SimpleScreen CRC blood test across the US - Medical Device Network
Abbott launches SimpleScreen CRC for Abbott Laboratories stock - AD HOC NEWS
Abbott Laboratories stock pre-market at EUR 87.30: plus 0.29 percent - AD HOC NEWS
DOJ Announces $385 Million Settlement to Resolve False Claims Allegations over Abbott Laboratories Baby Formula - MedLearn Publishing
CG Abbott plant included in $385M federal settlement - PinalCentral.com
Abbott (ABT) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Abbott (ABT) Stock May Be 25% Stretched After Biosensor Market Forecast - Simply Wall Street
Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch
Abbott Labs launches blood test to screen for colorectal cancer - Kenosha News
Mississippi receives $771K in Abbott formula settlement - wjtv.com
AG Fitch Announces False Claims Settlement with Abbott Laboratories - MageeNews.com
Mississippi to receive more than $771K in $384 million Abbott Laboratories settlement - Darkhorse Press
Abbott Laboratories (ABT) Launches SimpleScreen CRC As Fair Value Stays In Focus - Yahoo! Finance Canada
Mississippi to Receive $771K in $384M False Claims Settlement with Abbott Laboratories - tippahnews.com
Abbott Launches Simplescreen Crc Blood Test in the U.S - marketscreener.com
Abbott launches Freenome’s colorectal cancer screening test - MedTech Dive
In 1935, Grace Groner, a secretary, invested $180 in her employer Abbott; 75 years later, it had grown to - The Economic Times
Abbott Laboratories (NYSE:ABT): Are Investors Getting Over Their Scepticism Over The Company's Bold US$21bn Bet On Exact Sciences? - Stocks Down Under
Form 4 Abbott Laboratories For: 29 September By Investing.com - Investing.com UK
Abbott Laboratories stock at USD 100.95 on September 28, 2026 - AD HOC NEWS
Abbott lawsuit alleges spinal cord stimulators can fail, worsen nerve damage - Top Class Actions
Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032 - GlobeNewswire Inc.
Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? - Yahoo Finance
Abbott Laboratories Lobbying Profile, 2003 - OpenSecrets
3 Dividend Stocks To Watch As High Rates Test Defensive Shares - Simply Wall Street
Form 4 Abbott Laboratories For: 25 September By Investing.com - Investing.com India
At $103.99 a share, an Abbott Laboratories (ABT) director delivered or withheld shares for exercise costs or taxes. - Stock Titan
Abbott Laboratories stock falls 2.32 percent below yearly high effects? no - AD HOC NEWS
Is Abbott Laboratories (NYSE:ABT) Facing a Real Market Test? - Kalkine Media
Abbott Laboratories stock loses 1.82 percent before the bell - ad-hoc-news.de
How Lingo Partnership Will Impact Abbott Stock (ABT) - Simply Wall Street
Abbott to pay nearly $385 million to settle infant formula allegations - ConsumerAffairs
Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery - Yahoo Finance
Abbott Laboratories stock reports Q2 growth and earnings beat - AD HOC NEWS
Abbott Laboratories stock rises 0.69 percent ahead of the open - AD HOC NEWS
Abbott partners with Berry Street to add nutrition coaching to Lingo - Drug Delivery Business
Abbott Laboratories stock ends the day 0.69 percent higher at USD 103.69 - AD HOC NEWS
Abbott Laboratories: A Strong Business At A Fair Price (NYSE:ABT) - Seeking Alpha
Sinocare Asks Court To Rule Device Won't Infringe Abbott IP - Law360
What Makes Abbott Laboratories (ABT) an Attractive Opportunity? - Yahoo Finance
Abbott and Berry Street team up on personalized nutrition tracking - marketscreener.com
Is Abbott Laboratories (ABT) Still Undervalued On Volt’s First US And Canada Procedures? - Simply Wall Street
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Abbott and Berry Street partner to combine gluc... - Pluang
A 15% discount on Abbott's four-week glucose-monitor plans will go to Berry Street users. - Stock Titan
Abbott Laboratories stock gains 1.12 percent as settlement weighs - AD HOC NEWS
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.07%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):